Sofusbuvir And Velpatasvir 28ct

Sofosbuvir/velpatasvir antiviral combination; extralabel use in cats for treatment of FIP and hepatitis C-like viral infections. Sofosbuvir — NS5B RNA polymerase inhibitor prodrug. Mechanism: hepatically converted to active uridine nucleotide analogue → incorporates into viral RNA → chain termination of HCV/FCoV RNA replication. Used with velpatasvir for FIP in cats. Key information Sofosbuvir/velpatasvir — see above entry.

Oral tablets: Administer orally. May be given with food to improve compliance and reduce GI upset. Administer with food to reduce GI adverse effects. Wear gloves when handling. Administer daily — compliance critical for FIP treatment. Store at room temperature; protect from light. If a dose is missed Administer as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume the normal schedule. Never double up doses to make up for a missed one. Complete the course.

GI: vomiting, anorexia, diarrhea (cats). Renal: azotemia (monitor renal function). Hepatic effects (monitor liver enzymes). Generally well tolerated in FIP cats at therapeutic doses. Teratogenic (do not use in pregnant animals).

For animals Cats (FIP): administer with velpatasvir (NS5A inhibitor) for synergistic effect. Monitor renal and hepatic parameters. Reduce dose or extend interval in renal impairment. Monitor liver enzymes with prolonged use. Avoid in pregnant animals. For people handling this medication Wear gloves when handling. Wash hands thoroughly with soap and water after handling. Antiviral — Keep out of reach of children. Pregnant women and women of childbearing age should avoid contact. Wear gloves when handling. Teratogenic potential.

Contact your veterinarian. Limited overdose data. Contact vet for guidance.